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Introduction
The clinical excellence of an assisted reproductive technology 
(ART) program is demonstrated by the live birth of a healthy 
baby. The many painful injections administered throughout 
this difficult procedure seem unimportant after a healthy new-
born appears. Most women suffering from infertility tolerate 
this painful time. However, some women drop out of treat-
ment because of the injections (1). Mild ovarian stimulation 
protocols with clomiphene citrate/letrozole are significant 
considering that fewer injections are given and that the in vi-
tro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) 
treatment has a lower cost (2-3). Corifollitropin alfa is a good 
choice for ART cycles because fewer injections are needed 
than with other agents. Although the total cost of a corifol-
litropin alfa cycle is higher than that for the conventional con-
trolled ovarian hyperstimulation (COH) protocol, women tend 
to select corifollitropin alfa because of the lower number of 
injections.
Over the last decade, the gonadotropin hormone-releasing 
hormone (GnRH) antagonist cycle treatment protocol has 
been favored in ART programs. Although a meta-analysis of 
cycle outcomes comparing GnRH agonist and antagonist pro-
tocols reported similar results, women undergoing the GnRH-
antagonist program are administered fewer injections and 
the protocol is easier to perform than agonist protocols (4-5). 
However, some clinicians continue to prefer the long GnRH 
agonist cycle. Depot GnRH agonists have been used in ART 
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Abstract
programs before their integration into daily use and have result-
ed in reasonable outcomes (6-9). Furthermore, the drug indus-
try may force the use of these innovative options, making them 
more popular. The depot form of recombinant follicle-stimulat-
ing hormone (FSH; corifollitropin alfa) is another innovative op-
tion that allows for fewer injections during ART cycles.
In the present study, we compared the outcomes of a protocol 
combining the oldest version of the long protocol, which in-
cludes the depot form of GnRH agonist, with corifollitropin alfa 
to the outcomes of the GnRH-antagonist protocol, which is a 
rising star of the last decade.
Material and Methods
In this retrospective cohort, we analyzed luteal injected half-
dose depot GnRH agonist cycles in women who received 
corifollitropin alfa and those who underwent a conventional 
corifollitropin alfa cycle with a GnRH antagonist at the Division 
of Reproductive Endocrinology and IVF Unit, Obstetrics and 
Gynecology Department, Başkent University, Adana, Turkey, 
from March 2014 to August 2015. This study was approved by 
the Ethics committee of Başkent University. Ninety-four normal 
responding women were analyzed in this cohort. Women sus-
pected and/or defined as potential hyper-responders with poly-
cystic ovary syndrome (PCOS) and/or polycystic ovaries (PCO) 
were excluded and were not administered corifollitropin alfa 
because of the increased risk of ovarian hyperstimulation syn-
drome (OHSS).
Forty-five patients underwent the long protocol, in which a half-
dose of depot GnRH agonist (1.9 mg leuprolide acetate; Lucrin; 
Abbott France, Rungis Complexe, France) was administered 
on day 21 of the preceding cycle. If no cysts ≥2 cm were de-
tectable and estradiol (E2) was <50 pg/mL, weekly gonadotro-
pin stimulation with 150 µg corifollitropin alfa (150 µg Elonva, 
MSD; Haarlem, The Netherlands) was administered on the 
menstrual cycle day 3 after ovarian suppression was achieved. 
The estradiol and follicular monitoring continued until human 
chorionic gonadotropin (hCG) administration criteria were met 
and at least three follicles had maximum diameters >17 mm. 
Forty-nine patients underwent the GnRH-antagonist protocol. 
Corifollitropin alfa (Elonva 150 µg; MSD, The Netherlands) was 
administered on the menstrual cycle day 3. A GnRH antagonist 
(Orgalutran, MSD; The Netherlands) was added to this regimen 
on the last day of weekly gonadotropin administration, which 
was day 6 of stimulation. The hCG administration was applied 
with the guidance of ultrasound and estradiol monitoring until 
at least two or three follicles had maximum diameters >17 mm. 
The oocyte retrieval was performed 35–36 h after the hCG injec-
tion performed with a 17-gage needle under sedation. Embryos 
were transferred on day 3. All the patients had luteal support 
with 90 mg daily progesterone administered intravaginally (Cri-
none 8% gel, Merck Serono; Darmstadt, Germany) and 0.1 mg/
mL triptorelin on day 3 after embryo transfer. Clinical pregnancy 
was defined as the presence of at least one gestational sac, with 
detectable fetal cardiac activity by transvaginal ultrasonography.
The data expresses the means±SD. The baseline differences 
between the two groups were analyzed by Student’s t test. Pear-
son’s Chi-square test and Fisher’s exact test were used to com-
pare the ratios between groups. A value of p less than 0.05 was 
considered statistically significant. The data was analyzed using 
the Statistical Package for the Social Sciences (SPSS) for Win-
dows (version 17.0; SPSS, Inc.; Chicago, IL, USA).
Results
We performed 94 cycles with corifollitropin alfa in normal re-
sponding women during the 17 months of the study. The pa-
tients’ baseline characteristics were similar between the two 
groups (Table 1). The mean ages of the two groups were similar 
(32.77±5.55 vs. 34.2±4.51 years [“for the long- and antagonist-
protocol groups, respectively”]). Antimüllerian hormone (AMH) 
levels and mean antral follicle counts (AFC) of one ovary were 
also similar between the two groups (2.41±0.9 vs. 2.45±0.45 
ng/mL and 5.14±2.15 vs. 4.91±2.41, respectively) (Table 1). 
Although the mean E2 level on the day of hCG administration 
tended to be higher in women undergoing the depot-agonist 
protocol, the difference was not significant (2073.62±194.18 vs. 
1626.5±188.94 pg/mL). The total number of retrieved oocytes, 
the fertilization rate, and the number of transferred embryos 
were similar between the two groups (Table 1). The only sig-
nificant difference between the two protocols was the number 
of injections during the COH cycle, which included the depot-
agonist injection in the long-protocol group (4.46±1.64 vs. 
5.71±2.51, p=0.006) (Table 1).
The clinical pregnancy and implantation rates were similar in 
the two protocols (16/45 [35.6%] vs. 16/49 [32.7%] for the inten-
tion to treat and 32.5±6.82% vs. 36.25±8.58%, respectively) (Ta-
ble 2). Five and nine cycles were cancelled in the depot-agonist 
and GnRH-antagonist groups, respectively (Table 2). No moder-
ate or severe ovarian OHSS occurred in either group.
Discussion
Our results show that IVF/ICSI cycles could be performed with 
fewer injections using corifollitropin alfa and a half-dose of de-
pot GnRH agonist. The corifollitropin alfa and GnRH-antagonist 
cycle was introduced so that fewer injections would be needed. 
Our results show that the half-dose depot GnRH agonist plus 
corifollitropin alfa protocol resulted in fewer injections than 
were required in the GnRH-antagonist program in which cori-
follitropin alfa was used.
The combination of the depot form of GnRH agonist and cori-
follitropin alfa is a satisfactory option for patients who plan to 
drop out of IVF treatment because of the fear of multiple in-
jections. Use of a COH strategy with fewer injections is asso-
ciated with >50% reduction in dropout rate (1). Although our 
long protocol with a depot GnRH agonist is not considered to 
be a mild stimulation, it was superior to mild stimulation, as ap-
proximately only four injections were administered, the patients 
were satisfied, and a greater number of cryopreserved embryos 
were obtained. Another disadvantage of the protocol is the in-
creased risk for OHSS, which we did not encounter because of 
our proper selection of normal responding patients.
Depot GnRH agonists have been used since the last decade 
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of the 20th century. At that time, the depot agonist was recog-
nized as advantageous because of the attendant pituitary sup-
pression and the patient-friendly requirement of only a single 
injection. Hesitation to use a depot agonist was related to the 
concern that it might lead to pituitary oversuppression, which 
could cause a luteal phase defect because of the absence of 
pituitary luteinizing hormone (10, 11). However, the use of half-
dose depot GnRH for the COH cycle has resulted in reasonable 
IVF outcomes in infertile women (8-9). Therefore, we used half 
doses of the depot form of GnRH agonist to suppress the ovary. 
Furthermore, the ultra-long protocol, which includes 3 months 
of depot GnRH agonist injections to suppress the pituitary and 
endometriosis, seems to be the best choice in women with en-
dometriosis undergoing IVF/ICSI cycles (12-14). One random-
ized study that compared depot forms of a GnRH agonist and 
antagonist reported similar IVF/ICSI outcomes (15). No depot 
Table 1. Demographic and cycle characteristics of half-dose depot GnRH-agonist and GnRH-antagonist protocols in 
which corifollitropin alfa was used
 Depot GnRH agonist+ GnRH antagonist+ 
 corifollitropin alfa group (n=45) corifollitropin alfa group (n=49) p
Age (years) 32.77±5.55 34.2±4.51 0.17
BMI (kg/m2) 24.95±0.9 25.12±0.8 0.88
Duration of infertility (years) 5.23±3.01 4.72±3.46 0.45
AMH (m IU/L) 2.41±0.9 2.45±0.45 0.96
Antral follicle count  5.14±2.15 4.91±2.41 0.66
Follicle count >14 mm 11.18±5.3 10.79±6.51 0.75
E2 level (pg/mL) on hCG administration day 2073.62±194.18 1626.5±188.94 0.1
Progesterone level (ng/mL) on hCG administration day 1.07±0.22 0.88±0.07 0.42
Endometrial thickness (mm) 12.57±1.77 10.92±1.9 0.33
COH duration  9±2.29 8.36±2.58 0.21
Number of injections in the COH cycle 4.46±1.64 5.71±2.51 0.006
Retrieved oocytes (no.) 12.22±7.08 12.95±7.95 0.64
Metaphase II oocytes (no.) 9.81±6.29 10.8±6.82 0.47
Fertilization rate (%) 61.58±3.14 71.56±11.96 0.42
Embryo (no.) 6.65±4.95 6.29±3.63 0.7
Transferred embryos (no.) 1.48±0.55 1.63±048 0.22
Grade 1 embryos transferred (no.)  0.65±0.69 0.89±0.68 0.11
Grade 2 embryos transferred (no.) 0.8±0.85 0.69±0.86 0.57
Cryopreserved embryos (no.) 5.27±2.37 3.75±3.06 0.074
BMI: body mass index; AMH: antimüllerian hormone; COH: controlled ovarian hyperstimulation; E2: estradiol; hCG: human chorionic gonadotropin; GnRH: gonado-
tropin hormone-releasing hormone
Table 2. IVF/ICSI outcomes of half-dose depot GnRH-agonist and GnRH-antagonist protocols in which corifollitropin 
alfa was used
 Depot GnRH agonist+ GnRH antagonist+ 
 corifollitropin alfa group (n=45) corifollitropin alfa group (n=49) 
Positive β-hCG 18 (40%) 18 (36.7%) 0.93
CPR 16 (35.6%) 16 (32.7) 0.95
BPR 2 (4.44%) 2 (4.08%) NS
Implantation rate (%) 32.5±6.82 36.25±8.58 0.73
Singleton pregnancy rate 13/16 (81.25) 12/16 (75%) NS
Twin pregnancy rate 3/16 (18.75%) 4/16 (25%) NS
OHSS rate 0 0 NS
Cancel rate 5 (11.1%) 9 (18.4%) 0.46
CPR: clinical pregnancy rate; BPR: biochemical pregnancy rate; GnRH: gonadotropin hormone-releasing hormone; IVF/ICSI: in vitro fertilization/intracytoplasmic 
sperm injection; hCG: human chorionic gonadotropin; OHSS: ovarian hyperstimulation syndrome
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GnRH antagonists are marketed in Turkey, but they could be in-
cluded in another simple protocol with corifollitropin alfa.
The fundamental limitation of this study was the retrospective 
design. We did not perform a randomized trial because we did 
not want drug industry support for two reasons. First, our insti-
tute must pay all costs, including the costs of the COH cycles 
and patient insurance, when a randomized trial is conducted, 
making it too expensive to design a sufficiently powered ran-
domized study with high patient enrollment without industry 
support. Moreover, trials supported by a pharmaceutical com-
pany would be criticized as being biased in favor of a specific 
drug.
This is the first study to demonstrate similar IVF/ICSI results from 
a minimum-injection COH protocol compared with those from 
a more conventional method. This minimum-injection pro-
tocol is a welcome development that was appreciated by our 
patients. Our study focused on the long protocol, which most 
clinicians do not prefer. Additional well-designed randomized 
trials that compare depot GnRH agonists and antagonists with 
corifollitropin alfa are expected to demonstrate good IVF/ICSI 
outcomes.
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